<DOC>
	<DOC>NCT00268892</DOC>
	<brief_summary>The purpose of this extension study was to collect long-term safety and tolerability information to support a marketing authorisation application for a three-month dosage regimen of degarelix.</brief_summary>
	<brief_title>Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer</brief_title>
	<detailed_description>The data include data from the participants who participated in both the main study FE200486 CS15 (NCT00113753) and the extension study FE200486 CS15A.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has given written consent prior to any studyrelated activity is performed. A studyrelated activity is defined as any procedure that would not have been performed during the normal management of the patient. Has successfully completed the main study. Exclusion Criterion: Has been withdrawn from the main study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>